International Myeloma Society Educational Workshop in Belgrade, Serbia 2026

The International Myeloma Society Educational Workshop will be held in Belgrade, Serbia, from March 13 – 14, 2026, in collaboration with the Balkan Myeloma Study Group and the Serbian Myeloma Group. The event offers a dynamic program focused on the diagnosis, treatment, and monitoring of plasma cell malignancies. Attendees will benefit from lectures, roundtable discussions, and point-counterpoint conversations addressing current practices, challenging questions, and clinical cases.
Learning Objectives
Based on the program sessions, learners will be able to:

Implement updated diagnostic testing, imaging techniques, and MRD testing for Multiple Myeloma.

Apply new risk stratification models and effectively manage both Smoldering Myeloma and Newly Diagnosed Multiple Myeloma (transplant eligible and non-transplant eligible).

Determine optimal sequencing strategies for Relapsed and Refractory Multiple Myeloma and explore novel treatments beyond cell therapies.

Understand and incorporate novel immune strategies, including CAR T Cells and Bispecific T Cell Engagers, into clinical practice.

Manage myeloma-related complications such as bone disease, renal failure, and infections through appropriate supportive care and vaccinations.

Update knowledge on the management of other plasma cell disorders like Waldenström’s Macroglobulinemia and AL Amyloidosis.

Address challenging clinical scenarios, including relapse after T cell redirected therapies, extramedullary disease, and incorporating frailty into treatment algorithms.

Target Audience

This workshop is intended for hematologists, oncologists, researchers, and other healthcare professionals involved in the diagnosis, treatment, and ongoing care of patients with plasma cell malignancies.
Best for Hematologists and Oncologists.

Topics

Plenary Talks:

From Biology to Therapy: The Current Landscape of Multiple Myeloma.

The Future of Multiple Myeloma.

Diagnosis, Risk Stratification, and Monitoring of Plasma Cell Disorders:

Diagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up.

Update and Recommendations on Imaging Techniques in Myeloma.

MRD Testing in Multiple Myeloma.

New Risk Stratification in Smoldering and Multiple Myeloma.

Live Panel Discussion: Diagnosis and Follow Up of Patients.

Smoldering MM and Newly Diagnosed Multiple Myeloma:

Management of Clinical Significance/Smoldering Myeloma.

Management of Newly Diagnosed MM Transplant Eligible.

Management of Newly Diagnosed MM Non-transplant Eligible.

Live Panel Discussion: How to Manage SMM and NDMM.

Relapsed and Refractory Multiple Myeloma:

Optimal Sequencing for RRMM Patients in their 1st and 2nd Relapse.

Novel Treatments for MM Besides Cell Therapies and Bispecifics.

Live Panel Discussion: Sequencing of Therapies in RR MM.

Novel Immune Strategies:

CAR T Cells.

Bispecific T Cell Engagers.

Live Panel Discussion: Incorporating Novel Immunotherapies in Practice.

Supportive Care:

Bone Disease and Renal Failure.

Infection and Vaccinations.

Live Panel Discussion: Managing Myeloma Related Complications.

Update on Other Plasma Cell Disorders:

Waldenström’s Macroglobulinemia.

AL Amyloidosis.

Live Panel Discussion: Managing Other Dysporteinemias.

Challenging Questions in MM:

Relapse After T Cell Redirected Therapies.

Extramedullary Disease and Plasma Cell Leukemia.

Incorporating Frailty into Treatment Algorithms for MM.

Live Panel Discussion.